Psychosocial support for partners of patients with haemato-oncological disease - a group-based intervention to empower psychosocial health

Psycho-oncological intervention for partners of patients with haemato-oncological disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN16085028

Enrollment

144

Registered

2019-03-20

Start date

2019-09-01

Completion date

Unknown

Last updated

2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haemato-oncological diseases Cancer

Interventions

Participants will be either assigned to the intervention group (IG) or to the control group (CG). T1 is 3 months after the start of the intervention. Directly after the intervention, before t1, subjec

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who are diagnosed with a confirmed haematological neoplasia: incidences up to one year after diagnose or relapse, ICD-10 diagnoses: C81-C96 and D46, which are: Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma, multiple myeloma, myelodysplastic syndrome, acute or chronic leukaemia 2. Patients who have a partner 3. Patients and partners need to be aged between 18 and 70 years 4. Partners must be mentally and physically able to attend the program 5. Treatment modality and phase of illness is negligible for participation 6. Partners will be assigned to one of two study groups, given that PHQ-9 > 9 (depression) and GAD-7 > 9 (anxiety)

Exclusion criteria

Exclusion criteria: 1. Severe psychiatric disorders 2. Profound cognitive and physical impairment 3. An age limitation of 70 years aimed to minimise possible age-related comorbidities or mobility limitations

Design outcomes

Primary

Measure	Time frame
1. Depression measured using the PHQ-9 (Patient Health Questionnaire) at Screening, Baseline (prior to intervention), 3 months and 6 months later 2. Anxiety measured using the GAD-7 (Generalization Anxiety Disorder Scale) at Baseline (prior to intervention), 3 months and 6 months later	—

Secondary

Measure	Time frame
Measured prior to intervention, 3 months and 6 months later: 1. Quality of life, measured using Health Survey 12 (SF-12) 2. Fatigue, measured using Brief Fatigue Inventory (BFI) 3. Dyadic coping, measured using Dyadic Coping Inventory (DCI) 4. Attachment in close relationship, measured using Experience in close Relationships-Revised (ECR-RD) 5. Locus of control, measured using Internal, Powerful Others, and Chance Scale (IPC)	—

Measure

Time frame

Measured prior to intervention, 3 months and 6 months later: 1. Quality of life, measured using Health Survey 12 (SF-12) 2. Fatigue, measured using Brief Fatigue Inventory (BFI) 3. Dyadic coping, measured using Dyadic Coping Inventory (DCI) 4. Attachment in close relationship, measured using Experience in close Relationships-Revised (ECR-RD) 5. Locus of control, measured using Internal, Powerful Others, and Chance Scale (IPC)

—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 2, 2026